The recent surge in injection drug use (IDU) in Prague, Czech Republic, provided an opportunity to compare the distribution of hepatitis C virus (HCV) genotypes among recent injection drug users and nonusers. We provide evidence that the most common HCV subtype, 1b, has been circulating in Prague longer than the other subtypes but that IDU practice has magnified its recent prevalence, and that the primary drug of choice among IDU subjects appears to influence the prevalence of a particular HCV subtype.
The recent surge in injection drug use (IDU) in Prague, Czech Republic, provided an opportunity to compare the distribution of hepatitis C virus (HCV) genotypes among recent injection drug users and nonusers. We provide evidence that the most common HCV subtype, 1b, has been circulating in Prague longer than the other subtypes but that IDU practice has magnified its recent prevalence, and that the primary drug of choice among IDU subjects appears to influence the prevalence of a particular HCV subtype.
Viral hepatitis C (HCV) is a major emerging infectious disease problem worldwide. In the Czech Republic, the current anti-HCV antibody prevalence in the general population is estimated to be 0.5%-1% [1] . The recent increase in widespread injection drug use (IDU) in Central and Eastern Europe has led to a rapid emergence of HCV infections among the user population. The illicit drug market increased many-fold after political changes took place in Central and Eastern Europe in 1989. The Czech population of injection drug users represents a unique group when compared with similar populations in other countries that have longer history of IDU, because it consists of relatively young and healthy subjects, most of whom began the IDU habit only within the last decade. This history has provided us with an opportunity to study the recent introduction of HCV into this population and to compare the pattern of HCV genotype transmission and distribution in this population with that of the population of persons who do not use injection drugs who reside in the same geographic location. The aim of this study was to characterize the HCV genotype prevalence and its association with risk factors focused among injection drug users.
From October 1998 through January 2000, all patients with clinical symptoms and elevated liver enzymes who presented to 3 Prague hospitals and all patients who were referred to the hospitals because of suspicion of contact with known cases of hepatitis were prospectively asked to participate in the study at the time of their first visit. Those who gave consent were recruited into the study. All subjects were citizens of the Czech Republic who were residing in Prague. None of the patients were receiving antiviral treatment at the time of serum sample collection.
The study population consisted of 2 groups. Group 1 was composed of patients who reported IDU. The majority of these subjects were actively taking street drugs at the time of entry into the study. Group 2 was composed of patients with acute or chronic viral hepatitis (A, B, or C) or with abnormal liver enzymes without specific etiology who reported no current or past IDU.
Serum samples were tested locally for alanine aminotransferase (ALT) levels, and the reference range used for ALT was 10-47 U/L. ALT levels of 147 U/L were considered to be abnormal.
The diagnosis of viral hepatitis was made on the basis of the results of commercial, enzyme-linked immunosorbent assays (ELISA; HAV-IgM Assay, HAV-Total Assay, Monolisa AgHBsPlus, Monolisa anti-HBs 3.0, and Monolisa anti-HCV-Plus, version 2; BioRad SA). In addition to the ELISA, the diagnosis of hepatitis C was confirmed by the detection of HCV RNA using reverse-transcriptase PCR assay (Amplicor, Roche Molecular Systems). HIV infection status was assessed using ELISA (Genscreen, HIV-1/2, version 2, BioRad).
For genotyping purposes, viral RNA was extracted from 100-mL aliquots of serum by use of the method described by Boom et al. [2] . The conserved 5 -noncoding (5 NC) region of the virus was amplified according to a method described elsewhere [3, 4] . We sequenced the amplified 5 NC product that spans nucleotide positions Ϫ276 to Ϫ50 [5] and verified the genotypes by also sequencing a 222-bp amplified fragment within the NS5b region of the HCV genome [4] . Sequences were classified into HCV genotypes or subtypes according to the protocol reported by Simmonds et al. [4] and compared with prototype HCV genotype sequences (GenBank) using DNASIS (Hitachi). The accession numbers of the sequences used to compare the 5 NC sequences were as follows: 1a (M62321); 1b (D90208); 2a (D00944); 2b (D01221); 2c (D10075); 3a (D14307); 3b (D11443); 3c (D16612); 4a, Z4 (M84848); 4b (M84845); 4c (M84862); 4d (M84832); 4e M84828); 4f (M84829); 5a (M84860); and 6a (M84827). NS5b sequences were validated by comparison with other NS5b sequences deposited under the accession numbers L23435-L23475 [4] .
After they gave informed consent, subjects in groups 1 and 2 completed a standardized questionnaire. The data were analyzed by use of the computer software EpiInfo, version 6 
A total of 256 patients were consecutively recruited. All of the subjects tested negative for HIV. Of 256 patients, 126 (49%) tested positive for anti-HCV antibody, and, of these 126 subjects, 90 (71%) tested positive for HCV RNA by means of PCR. An additional 11 subjects with acute HCV tested positive for HCV RNA only (table 1) . These 101 PCR-positive patients consisted of 59 patients in group 1 (injection drug users) and 42 patients in group 2 (nonusers). Their demographic and clinical characteristics are shown in table 1. Sequence analyses of the PCR-amplified 5 NC and NS5b regions were completed for 92 of the 101 serum samples. The remaining 9 samples could not be typed because of weak PCR products. Of these 92 specimens, 87 (95%) contained HCV genotype 1, 1 (1%) contained genotype 2, 3 (3%) contained genotype 3, and 1 (1%) could not be typed. Genotypes 4-6 were not found. Of the 87 genotype 1 strains, 21 (24%) were subtype 1a and 66 (76%) were subtype 1b. The most common subtype in both groups was 1b.
The mean age of the subjects infected with HCV 1a for injection drug users was 22.4 years, whereas that of the nonusers was 29.7 years ( ). Of the subjects who were infected P p .049 with HCV 1b, the mean age of the injection drug users was 22.4 years, compared with 42.7 years for the nonusers (P ! ). The difference in mean ages of nonusers infected with .001 subtype 1a versus 1b was also significant (  ; table 2 ). P p .012 The standardized questionnaire was properly completed by 63% of the subjects. Risk factors for parenteral transmission, including blood transfusion, surgery, hemodialysis, tattooing, and body piercing, were not associated with any specific subtype infection (table 2) . However, among all injection drug users who were infected with genotype 1, 7 (58%) of 12 patients who reported using heroin as their primary drug of choice were infected with HCV subtype 1a, and 5 (42%) were infected with 1b; however, only 4 (18%) of 22 injection drug users who used methamphetamine as their primary drug of choice were infected with subtype 1a, and 18 (82%) were infected with subtype 1b ( ; Fisher's exact test; 2-tailed). P p .025 These observations suggest a distinct pattern of HCV genotype and subtype transmission in Prague populations. The recent surge in widespread practice of IDU in the Czech Republic has led to an epidemic of HCV infection among the injection drug-using population [1] . For new users, the risk of acquiring HCV can be as high as 65% in the first 6-12 months after beginning IDU [6] . We found that the genotype distribution of HCV among injection drug users and nonusers in Prague was similar: genotype 1 accounted for 90% of the infections in both groups. These results are in contrast to observations made by other investigators from Western Europe and Australia, where several studies reported association of HCV genotypes 1a and 3 with high-risk behaviors, such as illicit drug use [7, 8] . In these countries, where the practice of IDU has had a longer history, genotype 3 predominates among injection drug users [7, 8] . Of interest, in Croatia and Slovenia (former Republics in Yugoslavia), the HCV genotypic distribution is similar to that in Western Europe, and the most common genotype among the injection drug-using subpopulation was 3 [9, 10] . In our study, genotype 3 was found to be rare, but, as expected, all examples were found in the injection drug users.
In Prague, among those persons infected with HCV subtype 1b, the mean age of the injection drug users (22.4 years) was significantly lower than that of the nonusers (42.7 years). Even among the nonusers, those infected with HCV 1b were significantly older than were subjects infected with HCV 1a. These observations suggest that subtype 1b may have been present in Prague for a longer time period than subtype 1a. The recent increase in IDU may have amplified the prevalence of 1b among the injection drug-using population. The history of denying IDU by patients with hepatitis C is often met with skepticism. The large difference in the mean age of those infected with HCV subtype 1b strongly suggests that these 2 study groups had distinct risk factors. In Prague, IDU before 1989 was quite uncommon, and indeed, all nonusers except 1 reported a history of blood transfusion, surgery, or both. The primary drug of choice appears to determine HCV subtype infection among those who inject drugs in Prague, which suggests that distinct social networks may exist within this high-risk group. This study was limited by sample size and affected by the questionnaire response rate (63%). Continued studies of this population are necessary to strengthen our observations. The current epidemic of hepatitis C among the injection drug-using population in Prague may follow the way of the Western countries, as suggested by the appearance of genotype 3. What we learn in the Czech Republic may have relevance to other countries that are undergoing similar social changes that affect recent HCV hepatitis epidemiology.
